Skip to main content
. Author manuscript; available in PMC: 2013 Apr 15.
Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2011 Aug 12;50(10):991–1000. doi: 10.1016/j.jaac.2011.06.008

Figure 3. Eicosapentaenoic acid dose and Efficacy of Omega-3 Fatty Acid Supplementation for Attention-Deficit Hyperactivity Disorder (ADHD).

Figure 3

Note: Scatterplot of measured efficacy of omega-3 fatty acid supplementation in trials as a function of Eicosapentaenoic acid (EPA) dose utilized. Trials were weighted (size of circles) using the generic inverse variance method. Higher doses of EPA within essential fatty acids supplements was significantly associated with increased efficacy in treating ADHD symptoms (β=0.36 (95% CI: 0.01–0.72), t=2.34, p=0.04, R2=0.38). Two trials, Johnson 200839 (effect size=0.35, EPA dose=558mg weight=11.1%) and Richardson 200541 (effect size=0.36, EPA dose=558mg weight=17.3%) had overlapping point estimates on this figure. CI = confidence interval.